×
Manchester researchers use AI to simulate cancer patient trials
Written by
Published on
Join our daily newsletter for breaking news, product launches and deals, research breakdowns, and other industry-leading AI coverage
Join Now

AI-powered virtual cancer trials: Researchers at the University of Manchester and The Christie cancer hospital have received a £5.9 million grant from Cancer Research UK to develop AI-simulated clinical trials for cancer treatments.

  • The project aims to test the effectiveness of radiotherapy treatments on virtual patients created using real-life data, potentially accelerating research and reducing costs compared to traditional clinical studies.
  • Professor Rob Bristow, the lead researcher, emphasizes that these simulated trials will make cancer research “faster, safe and less expensive” than large-scale clinical studies involving real patients.
  • The AI-driven approach allows for faster testing of ideas and treatments compared to conventional trials, potentially leading to more rapid advancements in cancer care.

Historical context and radiotherapy background: The Christie hospital and Cancer Research UK have a long-standing history of pioneering radiotherapy research, dating back to the 1920s.

  • Radiotherapy, which uses X-ray radiation to kill cancer cells by damaging their DNA, remains a crucial treatment method in oncology.
  • The north-west of England sees an estimated 44,000 new cancer diagnoses each year, highlighting the importance of continued research and innovation in cancer treatment.

Project focus and funding details: The £5.9 million grant will support the research project for five years, with a specific emphasis on personalized cancer treatment and comparative studies.

  • Researchers will investigate patient-specific genetics and tumors to tailor treatments more effectively.
  • The team will compare a new form of proton beam therapy with standard radiotherapy for lung cancer patients, potentially identifying more effective treatment options.
  • The AI-powered virtual trials will allow for rapid testing of various treatments and devices, accelerating the research process.

Real-world impact and patient perspective: The potential benefits of this research extend beyond the laboratory, offering hope to cancer patients and survivors.

  • Martin Storey, a lung cancer survivor who participated in a clinical trial involving radiotherapy, expressed enthusiasm for the AI-driven approach to advancing cancer treatment.
  • Storey’s personal experience underscores the life-changing impact of cancer research and clinical trials, as he credits his survival to participating in a trial.
  • The use of AI and virtual trials could potentially increase the number of patients who benefit from cutting-edge treatments by streamlining the research process.

Future implications and potential outcomes: The integration of AI into cancer research represents a significant step forward in the field of oncology.

  • If successful, this approach could lead to more efficient and cost-effective clinical trials, potentially accelerating the development of new cancer treatments.
  • The focus on personalized medicine, considering patient-specific genetics and tumor characteristics, aligns with the broader trend towards precision oncology.
  • As AI technology continues to advance, it may play an increasingly important role in various aspects of cancer research and treatment, potentially improving outcomes for patients worldwide.
Radiotherapy: Manchester scientists use AI to simulate cancer patient trials

Recent News

Baidu reports steepest revenue drop in 2 years amid slowdown

China's tech giant Baidu saw revenue drop 3% despite major AI investments, signaling broader challenges for the nation's technology sector amid economic headwinds.

How to manage risk in the age of AI

A conversation with Palo Alto Networks CEO about his approach to innovation as new technologies and risks emerge.

How to balance bold, responsible and successful AI deployment

Major companies are establishing AI governance structures and training programs while racing to deploy generative AI for competitive advantage.